JP2002537102A - 吸着された高分子および微粒子を有するミクロエマルジョン - Google Patents

吸着された高分子および微粒子を有するミクロエマルジョン

Info

Publication number
JP2002537102A
JP2002537102A JP2000600618A JP2000600618A JP2002537102A JP 2002537102 A JP2002537102 A JP 2002537102A JP 2000600618 A JP2000600618 A JP 2000600618A JP 2000600618 A JP2000600618 A JP 2000600618A JP 2002537102 A JP2002537102 A JP 2002537102A
Authority
JP
Japan
Prior art keywords
microemulsion
microparticles
adsorbed
group
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000600618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002537102A5 (cg-RX-API-DMAC7.html
Inventor
デレック オハガン,
ギャリー エス. オット,
ジョン ドネリー,
ジナ カザズ,
ミルドレッド ウゴゾーリ,
マンモハン シンフ,
ジョン バラックマン,
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27382688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002537102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2002537102A publication Critical patent/JP2002537102A/ja
Publication of JP2002537102A5 publication Critical patent/JP2002537102A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Colloid Chemistry (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2000600618A 1999-02-26 2000-02-09 吸着された高分子および微粒子を有するミクロエマルジョン Withdrawn JP2002537102A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12185899P 1999-02-26 1999-02-26
US60/121,858 1999-02-26
US14639199P 1999-07-29 1999-07-29
US60/146,391 1999-07-29
US16199799P 1999-10-28 1999-10-28
US60/161,997 1999-10-28
PCT/US2000/003331 WO2000050006A2 (en) 1999-02-26 2000-02-09 Microemulsions with adsorbed macromoelecules and microparticles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011232182A Division JP6073053B2 (ja) 1999-02-26 2011-10-21 吸着された高分子および微粒子を有するミクロエマルジョン

Publications (2)

Publication Number Publication Date
JP2002537102A true JP2002537102A (ja) 2002-11-05
JP2002537102A5 JP2002537102A5 (cg-RX-API-DMAC7.html) 2007-04-05

Family

ID=27382688

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000600618A Withdrawn JP2002537102A (ja) 1999-02-26 2000-02-09 吸着された高分子および微粒子を有するミクロエマルジョン
JP2011232182A Expired - Lifetime JP6073053B2 (ja) 1999-02-26 2011-10-21 吸着された高分子および微粒子を有するミクロエマルジョン
JP2014110216A Withdrawn JP2014169323A (ja) 1999-02-26 2014-05-28 吸着された高分子および微粒子を有するミクロエマルジョン
JP2016125184A Pending JP2016172767A (ja) 1999-02-26 2016-06-24 吸着された高分子および微粒子を有するミクロエマルジョン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011232182A Expired - Lifetime JP6073053B2 (ja) 1999-02-26 2011-10-21 吸着された高分子および微粒子を有するミクロエマルジョン
JP2014110216A Withdrawn JP2014169323A (ja) 1999-02-26 2014-05-28 吸着された高分子および微粒子を有するミクロエマルジョン
JP2016125184A Pending JP2016172767A (ja) 1999-02-26 2016-06-24 吸着された高分子および微粒子を有するミクロエマルジョン

Country Status (9)

Country Link
US (4) US8206749B1 (cg-RX-API-DMAC7.html)
EP (3) EP1156781B1 (cg-RX-API-DMAC7.html)
JP (4) JP2002537102A (cg-RX-API-DMAC7.html)
AT (1) ATE297190T1 (cg-RX-API-DMAC7.html)
AU (1) AU2875700A (cg-RX-API-DMAC7.html)
CA (2) CA2363141C (cg-RX-API-DMAC7.html)
DE (1) DE60020677T2 (cg-RX-API-DMAC7.html)
ES (2) ES2579783T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000050006A2 (cg-RX-API-DMAC7.html)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524698A (ja) * 2003-04-25 2006-11-02 カイロン コーポレイション カチオン性微粒子およびhcve1e2dnaを含有する組成物ならびにその使用
JP2009514842A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントを含むスプリットインフルエンザワクチンにおけるth1/th2バランスの変化
JP2010522206A (ja) * 2007-03-22 2010-07-01 ピーディーエス バイオテクノロジー コーポレイション カチオン脂質による免疫応答の刺激
JP2010524945A (ja) * 2007-04-18 2010-07-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質で修飾されたナノ液滴、ならびにその合成物および製造方法
JP2013512892A (ja) * 2009-12-03 2013-04-18 ノバルティス アーゲー エマルジョンの微小流動化中および/または均質化中における成分の循環
JP2013531680A (ja) * 2010-07-06 2013-08-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
JP2015521601A (ja) * 2012-06-15 2015-07-30 ピーディーエス バイオテクノロジー コーポレイションPds Biotechnology Corporation カチオン性脂質ワクチン組成物および使用方法
JP2017014229A (ja) * 2009-07-31 2017-01-19 ラモット アット テル アビブ ユニバーシティ, リミテッド ポリヌクレオチド剤を含む細胞標的化ナノ粒子およびその使用
US10638750B2 (en) 2004-05-20 2020-05-05 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
US10729130B2 (en) 2004-01-23 2020-08-04 Eden Research Plc Nematicidal compositions and methods of using them
WO2020246584A1 (ja) * 2019-06-06 2020-12-10 デンカ株式会社 ペプチド核酸を基盤としたアジュバント
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2023518519A (ja) * 2020-04-13 2023-05-01 四川大学 マイクロエマルションに基づくワクチン送達システム、その製造方法及び使用
US11801257B2 (en) 2008-04-17 2023-10-31 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US11904015B2 (en) 2012-09-21 2024-02-20 Pds Biotechnology Corporation Vaccine compositions and methods of use
US12551460B2 (en) 2017-12-05 2026-02-17 Pds Biotechnology Coporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
WO2002026212A2 (en) 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
US20030138453A1 (en) * 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US6552004B1 (en) * 2000-10-30 2003-04-22 Universite De Montreal Delivery system for entrapping charged macromolecules and a method for preparing same
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
AU2002326561B2 (en) 2001-08-07 2008-04-03 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
EP1450856B1 (en) * 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ532274A (en) * 2001-10-03 2006-02-24 Chiron Corp Adjuvanted meningococcus compositions
KR20050048539A (ko) * 2001-10-06 2005-05-24 메리얼엘엘씨 CpG 제제 및 관련된 방법
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
JP4646516B2 (ja) 2002-02-20 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 吸着したポリペプチド含有分子を有する微粒子
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
US7884083B2 (en) 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
DK1861120T3 (en) 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
EP1871349A1 (en) * 2005-04-11 2008-01-02 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
JP2009504805A (ja) * 2005-08-09 2009-02-05 ナノバイオ コーポレーション 抗炎症活性を有するナノエマルジョン組成物
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052055A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
KR20080069232A (ko) * 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
CN101611048B (zh) 2006-12-12 2012-11-07 赛托斯生物技术公司 含有高浓度鸟嘌呤单体的寡核苷酸
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CA2715460C (en) 2008-02-13 2020-02-18 President And Fellows Of Harvard College Continuous cell programming devices
CN103990120B (zh) * 2008-04-01 2018-06-05 伊耐特免疫治疗有限公司 抗感染剂及其用途
JP2011518184A (ja) * 2008-04-18 2011-06-23 ナノバイオ コーポレーション ヘルペスウイルス感染の治療方法
CA2721800A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
US8226965B2 (en) 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
WO2009132343A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating onchomycosis
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
WO2010036945A2 (en) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
EP3020412B1 (en) * 2009-06-16 2017-10-11 The Regents of the University of Michigan An immunogenic composition comprising nanoemulsion inactivated rsv
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
AU2013202706B2 (en) * 2009-12-03 2016-02-11 Seqirus UK Limited Circulation of components during microfluidization and/or homogenization emulsions
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
SG10201501612RA (en) 2009-12-03 2015-04-29 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20200310T1 (hr) 2010-10-06 2020-08-21 President And Fellows Of Harvard College Hidrogelovi koji stvaraju pore pogodni za injekcije, namijenjeni staničnim terapijama na bazi materijala
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
JP6205360B2 (ja) * 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
MX344635B (es) * 2012-03-23 2017-01-04 Amicrobe Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
EP2851066A1 (en) * 2013-09-23 2015-03-25 LTS LOHMANN Therapie-Systeme AG Fixation of vaccine formulations on devices for epidermal immunisation by oily adjuvants
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP4112076A1 (en) * 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
MX391930B (es) 2015-01-16 2025-03-21 Zoetis Services Llc Vacuna contra la fiebre aftosa.
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US11123740B2 (en) 2015-06-29 2021-09-21 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
SMT202200310T1 (it) 2015-12-23 2022-09-14 Modernatx Inc Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
WO2017136837A1 (en) 2016-02-06 2017-08-10 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
CN110740813B (zh) 2016-11-28 2022-06-03 亚利桑那州立大学董事会 涉及连续流动液滴反应的系统和方法
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
CN110740744A (zh) 2017-04-06 2020-01-31 艾麦克罗比公司 性能和安全性增强的局部施用的抗微生物剂的组合物和应用
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US12220486B2 (en) 2018-03-02 2025-02-11 Saint Joseph's University Polymer compositions for storage and release of polypeptides
CN112236218B (zh) 2018-04-02 2022-04-26 滴管公司 用于连续流乳液处理的系统和方法
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
JP2022514568A (ja) 2018-12-17 2022-02-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫系のモジュレーションのための生物工学的スキャフォールドおよびその使用
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
AU2020351220A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Sars-cov-2 rnaワクチン組成物および使用方法
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033487A1 (en) * 1997-01-30 1998-08-06 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
WO1998033932A1 (en) * 1997-01-31 1998-08-06 Korea Institute Of Science And Technology Lipid emulsions as gene transfection agents and method of preparing said emulsions
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999004761A1 (en) * 1997-07-22 1999-02-04 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions of lipid particles comprising a lipid agent and a protein
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1565298A (en) 1925-12-15 Stop check announcing device for adding machines
CA583561A (en) 1959-09-22 H. Edgerton William Therapeutically valuable esters and methods for obtaining the same
US1573698A (en) 1922-06-21 1926-02-16 Union Carbide & Carbon Res Lab Denatured alcohol
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
FR1317586A (cg-RX-API-DMAC7.html) 1961-03-17 1963-05-08
BE634667A (cg-RX-API-DMAC7.html) 1962-07-11
BE755269A (fr) 1969-08-25 1971-02-01 Westinghouse Electric Corp Systeme de regulation d'epaisseur du produit lamine sortant d'un laminoir
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4772466A (en) 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5324513A (en) 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
EP0628633B1 (en) 1984-04-06 2003-01-08 Chiron Corporation Recombinant herpes simplex gB-gD vaccine
US5098704A (en) 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4689225A (en) 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4826957A (en) 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
JP2661044B2 (ja) 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
DK341386D0 (da) 1986-07-18 1986-07-18 Voetman Karin Glassau Fremgangsmaade og apparat til oprulning af flade dejstykker, f.eks. til roulader
EP0289550B1 (en) 1986-10-20 1996-04-10 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
ES2097840T3 (es) 1987-11-03 1997-04-16 Syntex Inc Adyuvante de vacuna que comprende un tetrapoliol.
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
EP0436537A4 (en) 1988-01-29 1992-04-08 Chiron Corporation Recombinant cmv neutralizing proteins
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
WO1990014436A1 (en) 1989-05-18 1990-11-29 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
CH679207A5 (cg-RX-API-DMAC7.html) 1989-07-28 1992-01-15 Debiopharm Sa
WO1992000081A1 (en) * 1990-06-29 1992-01-09 Chiron Corporation Vaccine compositions containing liposomes
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JPH0827018A (ja) 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US5814516A (en) 1995-10-13 1998-09-29 Lockheed Martin Energy Systems, Inc. Surface enhanced Raman gene probe and methods thereof
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
GB9608803D0 (en) 1996-04-27 1996-07-03 Univ Newcastle Mitochondrial dna defects
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US5821060A (en) 1996-08-02 1998-10-13 Atom Sciences, Inc. DNA sequencing, mapping, and diagnostic processes using hybridization chips and unlabeled DNA
JP2001501825A (ja) 1996-10-04 2001-02-13 ダコ アクティーゼルスカブ マイコバクテリア(Mycobacteria)の検出のための新規プローブ
DE19640974A1 (de) 1996-10-04 1998-04-16 Bayer Ag Bausteine für DNA/PNA-Cooligomere
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
EP0939762A2 (en) 1996-11-05 1999-09-08 Clinical Micro Sensors Electrodes linked via conductive oligomers to nucleic acids
US5800999A (en) 1996-12-16 1998-09-01 Tropix, Inc. Dioxetane-precursor-labeled probes and detection assays employing the same
WO2000006123A1 (en) 1998-07-29 2000-02-10 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
CA2228875A1 (en) 1997-02-08 1998-08-08 Boehringer Mannheim Gmbh A method for the preparation of nucleic acid binding compound
US5962230A (en) 1997-02-13 1999-10-05 The University Of Connecticut Diagnosis and treatment of glaucoma
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE19712530A1 (de) 1997-03-25 1998-10-01 Boehringer Mannheim Gmbh Neue Monomerbausteine zur Markierung von peptidischen Nukleinsäuren
US6086900A (en) 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
CA2295740A1 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6045816A (en) * 1998-06-17 2000-04-04 Isp Investments Inc. Water-based microemulsion of a pyrethroid
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
KR100701569B1 (ko) 2006-07-10 2007-03-29 주식회사 경동나비엔 응축방지를 위한 저장식 보일러의 열교환기 구조
EP2019117A1 (en) 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimized purification process of recombinant growth factor protein
JP5704163B2 (ja) 2010-03-12 2015-04-22 コニカミノルタ株式会社 分子間相互作用の検出方法およびその検出装置
JP6136343B2 (ja) 2012-06-12 2017-05-31 株式会社リコー 情報処理システム、情報処理方法、プログラム、及び記録媒体
AT514720B1 (de) 2013-08-30 2016-03-15 Blum Gmbh Julius Stellvorrichtung
CN104683216B (zh) 2013-11-29 2019-04-12 腾讯科技(深圳)有限公司 客服信息的转发方法及装置、客服系统
JP6287387B2 (ja) 2014-03-12 2018-03-07 株式会社リコー 液滴吐出装置の液体粘度検出方法、液滴吐出装置の制御方法、液滴吐出装置、及び液滴吐出装置の液体粘度を検出する回路
FR3030069B1 (fr) 2014-12-16 2020-03-20 Zrc Geneve Sa Montre a lunette tournante
KR102354328B1 (ko) 2015-09-22 2022-01-21 삼성전자주식회사 영상 표시 장치 및 그 동작 방법
US9680022B1 (en) 2016-07-12 2017-06-13 United Microelectronics Corp. Semiconductor device having silicon-germanium layer on fin and method for manufacturing the same
JP2020112507A (ja) 2019-01-16 2020-07-27 日本電信電話株式会社 案内文生成装置、案内システム、案内文生成方法及びプログラム

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033487A1 (en) * 1997-01-30 1998-08-06 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
WO1998033932A1 (en) * 1997-01-31 1998-08-06 Korea Institute Of Science And Technology Lipid emulsions as gene transfection agents and method of preparing said emulsions
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999004761A1 (en) * 1997-07-22 1999-02-04 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions of lipid particles comprising a lipid agent and a protein
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524698A (ja) * 2003-04-25 2006-11-02 カイロン コーポレイション カチオン性微粒子およびhcve1e2dnaを含有する組成物ならびにその使用
US10729130B2 (en) 2004-01-23 2020-08-04 Eden Research Plc Nematicidal compositions and methods of using them
US10638750B2 (en) 2004-05-20 2020-05-05 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
JP2009514842A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントを含むスプリットインフルエンザワクチンにおけるth1/th2バランスの変化
JP2010522206A (ja) * 2007-03-22 2010-07-01 ピーディーエス バイオテクノロジー コーポレイション カチオン脂質による免疫応答の刺激
US11911359B2 (en) 2007-03-22 2024-02-27 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP2014058525A (ja) * 2007-03-22 2014-04-03 Pds Biotechnology Corp カチオン脂質による免疫応答の刺激
JP2010524945A (ja) * 2007-04-18 2010-07-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質で修飾されたナノ液滴、ならびにその合成物および製造方法
US11801257B2 (en) 2008-04-17 2023-10-31 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP2017014229A (ja) * 2009-07-31 2017-01-19 ラモット アット テル アビブ ユニバーシティ, リミテッド ポリヌクレオチド剤を含む細胞標的化ナノ粒子およびその使用
US10179113B2 (en) 2009-07-31 2019-01-15 Ramot At Tel-Aviv University Ltd. Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
KR101523215B1 (ko) * 2009-12-03 2015-05-27 노파르티스 아게 에멀션 미세 액화 및/또는 균질화 동안 성분들의 순환
JP2013512892A (ja) * 2009-12-03 2013-04-18 ノバルティス アーゲー エマルジョンの微小流動化中および/または均質化中における成分の循環
JP2013531680A (ja) * 2010-07-06 2013-08-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
US12201685B2 (en) 2012-06-15 2025-01-21 Pds Biotechnology Corporation Methods of modulating immune responses with cationic lipid vaccine compositions
JP2015521601A (ja) * 2012-06-15 2015-07-30 ピーディーエス バイオテクノロジー コーポレイションPds Biotechnology Corporation カチオン性脂質ワクチン組成物および使用方法
US11904015B2 (en) 2012-09-21 2024-02-20 Pds Biotechnology Corporation Vaccine compositions and methods of use
US11911465B2 (en) 2012-09-21 2024-02-27 Pds Biotechnology Corporation Vaccine compositions and methods of use
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11638753B2 (en) 2015-11-13 2023-05-02 PDS Biotechnology Corporalion Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US12551460B2 (en) 2017-12-05 2026-02-17 Pds Biotechnology Coporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
JP7602457B2 (ja) 2019-06-06 2024-12-18 デンカ株式会社 ペプチド核酸を基盤としたアジュバント
US12016920B2 (en) 2019-06-06 2024-06-25 Denka Company Limited Adjuvant based on peptide nucleic acid
JPWO2020246584A1 (cg-RX-API-DMAC7.html) * 2019-06-06 2020-12-10
WO2020246584A1 (ja) * 2019-06-06 2020-12-10 デンカ株式会社 ペプチド核酸を基盤としたアジュバント
JP7475733B2 (ja) 2020-04-13 2024-04-30 四川大学 マイクロエマルションに基づくワクチン送達システム、その製造方法及び使用
JP2023518519A (ja) * 2020-04-13 2023-05-01 四川大学 マイクロエマルションに基づくワクチン送達システム、その製造方法及び使用
US12539272B2 (en) 2020-04-13 2026-02-03 Sichuan University Microemulsion-based vaccine delivery system, preparation method therefor and use thereof
KR102950449B1 (ko) * 2020-04-13 2026-04-09 시추안 유니버시티 마이크로에멀젼 기반 백신 전달 시스템 및 그 제조 방법, 용도

Also Published As

Publication number Publication date
CA2363141C (en) 2010-04-06
AU2875700A (en) 2000-09-14
CA2689696C (en) 2013-08-06
WO2000050006A3 (en) 2001-01-18
US20130195898A1 (en) 2013-08-01
US8309139B2 (en) 2012-11-13
JP2012017344A (ja) 2012-01-26
EP1574210A3 (en) 2007-02-21
ATE297190T1 (de) 2005-06-15
US8771747B2 (en) 2014-07-08
US20070116709A1 (en) 2007-05-24
US8206749B1 (en) 2012-06-26
WO2000050006A2 (en) 2000-08-31
EP1574210B1 (en) 2016-04-06
CA2689696A1 (en) 2000-08-31
JP2014169323A (ja) 2014-09-18
EP1574210A2 (en) 2005-09-14
US20130195923A1 (en) 2013-08-01
ES2579783T3 (es) 2016-08-16
JP6073053B2 (ja) 2017-02-01
EP2286792A1 (en) 2011-02-23
EP1156781A2 (en) 2001-11-28
DE60020677D1 (de) 2005-07-14
DE60020677T2 (de) 2006-05-04
ES2242604T3 (es) 2005-11-16
CA2363141A1 (en) 2000-08-31
JP2016172767A (ja) 2016-09-29
US8734832B2 (en) 2014-05-27
EP1156781B1 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
JP6073053B2 (ja) 吸着された高分子および微粒子を有するミクロエマルジョン
US8541023B2 (en) Immunogenic compositions containing phospholipid
CA2528007C (en) Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
CA2420621C (en) Microparticle compositions and methods for the manufacture thereof
EP0991403B1 (en) Use of microparticles with adsorbed antigen to stimulate immune responses
US7501134B2 (en) Microparticles with adsorbed polypeptide-containing molecules
JP2002508334A (ja) サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
JP2003502388A5 (cg-RX-API-DMAC7.html)
PT1585542E (pt) Composições imunogénicas contendo fosfolípido

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100709

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111101

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120530

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120703

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120731